• Mashup Score: 3

    were treated with tofacitinib and followed up. Clinical and laboratory data of these patients were recorded between January 2019 and June 2022. SPSS was used for all statistical analyses. Results The mean age of patients with MDA5+DM was 45 ± 12.4 years, and the median disease duration was 6.5 months (range, 3–13 months). The mean dosage of glucocorticoids was 34.7 ± 20.9 mg/d at the initiation of tofacitinib therapy. Overall, 47 patients were followed up for a mean duration of 7.8 ± 6.2 months. We found that the clinical symptoms of 28 patients (59.6%) were improved, but 1 patient (2.1%) died because of severe infection. Moreover, complications occurred in 25 patients (53.2%), among whom 19 patients had infections. Older age and C-reactive protein levels close to the upper value in reference range at the initial treatment were found to be the potential risk factors of infection. Furthermore, patients with cutaneous ulcers were found to have a lower risk of infection. Conclusion Tofaci

    Tweet Tweets with this article
    • Efficacy and safety of tofacitinib for the treatment of anti-MDA5 antibody-positive #Dermatomyositis https://t.co/D5R6QATW1f #Rheumtwitter #Myositis

  • Mashup Score: 0

    Guiding patients with juvenile dermatomyositis from pediatric to adult care is essential to minimize comorbidities and complications, according to data presented at EULAR 2022 Congress.“A 4-year-old is very different than a 16-year-old,” Liza McCann, MD, of the Alder Hey Children’s National Health Service Foundation Trust, in the United Kingdom, said in her presentation.

    Tweet Tweets with this article
    • Guiding patients with juvenile #dermatomyositis from pediatric to adult care is essential to minimize comorbidities and complications #EULAR2022 #Rheumatology https://t.co/t6BRlvWfnT

    • Guiding patients with juvenile #dermatomyositis from pediatric to adult care is essential to minimize comorbidities and complications #EULAR2022 #Rheumatology https://t.co/bUKzMJbPAV